Updated Jul 16, 2026
Rojkjaer Lisa has filed 2 SEC Form 4 filings across 1 company in the last 90 days.

Lisa Rojkjaer is the Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. She has a background in medicine and drug development, contributing to the company's clinical strategies.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-03 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 850 | $29.86 | $25K |
| 2026-02-19 | RIGL | RIGEL PHARMACEUTICALS INC | A — Grant or award | 18.9K | $0.00 | |
| 2026-02-12 | RIGL | RIGEL PHARMACEUTICALS INC | F — Tax withholding / forfeiture | 3.8K | $34.62 | $130K |
Lisa Rojkjaer is the Executive Vice President and Chief Medical Officer at Rigel Pharmaceuticals Inc, a company focused on developing small-molecule drugs for various diseases. She has a background in medicine and drug development, contributing to the company's clinical strategies.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Rojkjaer Lisa profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.